Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors
Zachariah Thomas, Andrew C Johns, Michael Glover, Emanuele Crupi, Yago L Nieto, John F Ward, Jose A Karam, Wayne L Hofstetter, Monica Desai, Seungtaek L Choi, Amishi Y Shah, John Lin, Mohammad Jad Moussa, Cindy Y Jiang, Omar Alhalabi, Matthew T CampbellAbstract
Purpose
Somatic-type malignancy (SM) of germ cell tumor (GCT) is rare but demonstrates aggressive behavior. Differences by primary site, time to transformation, and mutational status remains poorly characterized.
Patients and Methods
We reviewed all SM patients from June 2016 - May 2025 at a tertiary referral center. Time to somatic transformation (TST) was defined from initial GCT diagnosis to SM detection. SM were classified based on time of detection- at initial diagnosis (de novo), at consolidative surgery, relapse under 5 years, and evolved SM- relapse after 5 years. Descriptive statistics, Kaplan–Meier estimates, and Cox regression analyses were used.
Results
72 patients were identified: 40 (56%) with testicular, 24 (33%) with mediastinal, and 8 (11%) with other primaries. 22/24 (92%) mediastinal tumors with SM had sarcomatous transformation. Sarcoma was seen in 25/42 (60%) of de novo SM while adenocarcinoma was detected as an evolved entity in 5/6 (83.3%) cases. Embryonic type neuroectodermal tumor (ENET) histology carried poor prognosis compared to non-ENET histology (median OS 1.8 vs 8 years; HR 1.94, p = 0.1). Genomic data available showed PTEN-AKT-mTOR pathway mutations (33%) and TP53 mutations (33%), enriched in extra-gonadal sarcomatous SM.
Conclusions
SM exhibits temporal, histologic, and molecular distinctions across primary sites. Response to front-line therapy and survival outcomes are poor. Future direction includes the exploration of underlying predictors of transformation and identification of targetable alterations in the relapsed setting.